Drug firm Wockhardt has received approval from the US health regulator for its generic Oxacillin injection used for treatment of bacterial infections, the company said today.
The company has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxacillin injections in the strengths of 1 gm and 2 gm, Wockhardt said in a filing to the BSE.
The company is expected to launch this product in the United States soon, it added.
"The product is being manufactured at a contract manufacturing facility, based near Milan, Italy," Wockhardt said.
Oxacillin, an antibiotic, is used to treat many different infections caused by penicillin-resistant Staphylococcal and other bacterias, including urinary tract infections, respiratory tract issues, septicemia, wounds and bacterial meningitis, among others, it added.
Wockhardt is trading at Rs 603.15 in the afternoon trade on the BSE, up 0.63 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)